What does Pliant Therapeutics, Inc. do?
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b…
What is Pliant Therapeutics, Inc.'s P/E and P/B ratio?
Pliant Therapeutics, Inc. has a P/E ratio of -0.6 and a P/B ratio of 0.36.
What is Pliant Therapeutics, Inc.'s debt-to-equity ratio?
Pliant Therapeutics, Inc. has a debt-to-equity ratio of 0.20.
How much does Pliant Therapeutics, Inc. owe compared with what it owns?
Pliant Therapeutics, Inc. owes $0.23 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Pliant Therapeutics, Inc.'s Positivity rank?
Pliant Therapeutics, Inc. is ranked #2,509 of 6,775 companies globally and #797 of 3,999 in United States on PositoAI, with a Positivity Score of 21,496.
Does Pliant Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Pliant Therapeutics, Inc..
Where can I read the latest news about Pliant Therapeutics, Inc.?
Recent headlines about Pliant Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Pliant Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Pliant Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.